Trial Profile

Rivastigmine in the treatment of Sleep REM Behaviour Disorder (RBD) and Hallucinations in Parkinsonism: a Clinical and Polysomnographic study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivastigmine (Primary)
Indications Hallucinations; Parkinsonian disorders; Sleep disorders
Focus Pharmacodynamics

Most Recent Events

24 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
30 Jan 2012 Primary endpoint 'REM-sleep' has been met according to results published in Movement Disorders.
30 Jan 2012 Results published in Movement Disorders.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com